See more : T Stamp Inc. (IDAI) Income Statement Analysis – Financial Results
Complete financial analysis of IGM Biosciences, Inc. (IGMS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IGM Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Advanced Wireless Semiconductor Company (8086.TWO) Income Statement Analysis – Financial Results
- Companhia Energética de Brasília – CEB (CEBR5.SA) Income Statement Analysis – Financial Results
- Elite Material Co., Ltd. (2383.TW) Income Statement Analysis – Financial Results
- Pointerra Limited (3DP.AX) Income Statement Analysis – Financial Results
- GSE Systems, Inc. (GVP) Income Statement Analysis – Financial Results
IGM Biosciences, Inc. (IGMS)
About IGM Biosciences, Inc.
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 2.13M | 1.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| Gross Profit | -6.15M | -9.53M | -7.72M | -3.58M | -2.33M | -278.00K | -161.00K |
| Gross Profit Ratio | -288.59% | -891.77% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 215.52M | 179.29M | 127.03M | 65.03M | 35.26M | 18.96M | 8.64M |
| General & Administrative | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 50.07M | 49.74M | 38.30M | 18.25M | 9.24M | 3.83M | 2.51M |
| Other Expenses | 0.00 | -181.00K | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Operating Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Cost & Expenses | 265.59M | 229.03M | 165.32M | 83.28M | 44.50M | 22.79M | 11.15M |
| Interest Income | 17.74M | 7.04M | 159.00K | 1.93M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28M | 10.60M | 7.72M | 3.58M | 2.33M | 278.00K | 161.00K |
| EBITDA | -253.36M | -221.88M | -157.44M | -77.78M | -40.80M | -22.51M | -10.99M |
| EBITDA Ratio | -11,894.74% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -263.46M | -227.96M | -165.32M | -83.28M | -44.50M | -22.79M | -11.15M |
| Operating Income Ratio | -12,369.06% | -21,324.23% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 17.72M | 6.85M | 159.00K | 1.93M | 1.37M | 80.00K | 93.00K |
| Income Before Tax | -245.74M | -221.10M | -165.16M | -81.36M | -43.13M | -22.71M | -11.05M |
| Income Before Tax Ratio | -11,537.00% | -20,683.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 678.00K | -6.85M | -4.48M | -1.03M | -597.00K | 80.00K | 0.00 |
| Net Income | -246.42M | -214.25M | -160.68M | -80.33M | -42.54M | -22.71M | -11.05M |
| Net Income Ratio | -11,568.83% | -20,041.91% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| EPS Diluted | -4.71 | -5.16 | -4.80 | -2.61 | -4.73 | -51.84 | -25.24 |
| Weighted Avg Shares Out | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
| Weighted Avg Shares Out (Dil) | 52.31M | 41.54M | 33.48M | 30.75M | 9.00M | 438.07K | 437.94K |
IGM Biosciences to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call and Webcast on March 30, 2023
First patient dosed in the phase 2a part of Medivir's study with fostrox in combination with Lenvima®
Medivir to present at the Erik Penser Bank Healthcare Day
Pia Baumann takes up her position as Chief Medical Officer
IGM Biosciences to Present at the Guggenheim 2023 Oncology Conference
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
IGM Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Medivir has completed a successful pre-IND meeting with the FDA
IGM Biosciences Presents Data from T cell Engager Portfolio for Hematologic Malignancies at 2022 American Society of Hematology Annual Meeting
IGM Biosciences to Present at the Bank of America Biotech SMID Cap Conference
Source: https://incomestatements.info
Category: Stock Reports